04/08/2026
In 2020, researchers at Semmelweis University in Budapest gave rats a sub-psycdelic dose of ÄMT after inducing an ischemic stroke.
The result: the dead-tissue zone shrank significantly, and within 30 days the rats recovered near-complete motor function.
85% of stroke patients today receive no interventional treatment. Your brain loses 1.9 million neurons every minute a stroke goes untreated. There is almost nothing available for the majority of people who suffer from a stroke.
Now Algernon NeuroScience has cleared the final regulatory hurdles for a 40-patient, double-blind Phase 2a trial in Hungary. Stroke patients will receive an IV drip of ÄMT, at a dose low enough to cause zero psycdelic effects, within 24 hours of diagnosis.
ÄMT already occurs naturally in the human brain. Your body produces it during cardiac arrest, childbirth and right bf you die. This isnāt a fringe molecule. Itās one of the most ancient compounds in human biology.
The Phase 1 trial confirmed safety at sub-psychedelic levels. The Phase 2a will be the first time ÄMT is tested on actual stroke patients.
We are barely scratching the surface of what these molecules can do.
Sources:
Nardai S. et al., āN,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats.ā Experimental Neurology, May 2020. doi: 10.1016/j.expneurol.2020.113245
LaĢszloĢ MJ. et al., āN,N-dimethyltryptamine mitigates experimental stroke by stabilizing the blood-brain barrier and reducing neuroinflammation.ā Science Advances, Aug 2025. doi: 10.1126/sciadv.adx5958
Saver JL., āTime Is Brain ā Quantified.ā Stroke, Jan 2006. doi: 10.1161/01.STR.0000196957.55928.ab
Algernon NeuroScience Phase 2a trial announcement, Feb 2025 ā algernonneuroscience.com
GBD 2021 Stroke Collaborators ā The Lancet, 2024